Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation

Launched by EMORY UNIVERSITY · Oct 25, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how offering hearing tests close to home or through remote options can help monitor hearing loss in patients with certain types of head and neck cancers who are receiving treatment with cisplatin chemotherapy and/or radiation. These treatments can sometimes lead to hearing loss, which can affect a person’s quality of life, making it hard to communicate and connect with others. The goal of the study is to see if easier access to hearing tests can help identify changes in hearing early, allowing for adjustments in treatment to prevent further loss.

To participate in this trial, you need to be an adult (18 years or older) with a confirmed diagnosis of head and neck squamous cell carcinoma who will be treated with cisplatin and/or radiation. You should also expect to have your hearing tested before, during, and after your treatment, which may be done in a way that is more convenient for you, especially if you live far from a medical center. It's important to note that if you have severe hearing loss already, you may not be eligible for this trial. The trial is currently recruiting participants, and your involvement could help improve how we monitor and manage hearing loss in patients like you.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients, male or female, aged ≥ 18, able to provide informed consent
• • Subjects with pathologically proven HNSCC involving the oral cavity, oropharynx, larynx, hypopharynx, nasopharynx, skin, or paranasal sinuses; patients with unknown primary HNSCC involving the cervical lymph nodes can also be included. Patients can have previously untreated or recurrent/metastatic disease
• • Subjects who will be treated with cisplatin chemotherapy and/or radiation. For radiation alone, patients should have tumors near the inner ear, including the nasopharynx, temporal bone, and/or parotid salivary gland
• • Life expectancy of more than 3 months, as determined by the investigator
• Exclusion Criteria:
• • Patients with profound hearing loss in both ears, which precludes an accurate hearing test. This can be determined based on patient report/history or audiogram done before or after informed consent
• • Patients who are unable to participate in a hearing test (per the investigator's judgment)